查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404792

癌症診斷藥物的全球市場：規模、佔有率和趨勢分析報告 - 按產品、按類型、按應用、按最終用途、按測試類型、細分市場預測，2024-2030 年

Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Type (IVD, LDT), By Application (Breast Cancer, Lung Cancer), By End-use, By Test Type, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 240 Pages | 商品交期: 2-10個工作天內

價格

癌症診斷藥物市場成長與趨勢：

預計到2030年，全球癌症診斷市場規模將達到1,623.1億美元。

預計2024年至2030年該市場將以6.16%的複合年成長率擴張。多個組織加強癌症意識提升計劃是全球診斷產品需求增加的一個主要因素。國家子宮頸癌聯盟、世界衛生組織、疾病預防控制中心、美國預防服務工作小組和其他機構為增加子宮頸癌篩檢而建立的夥伴關係和協作是預計在預測期內推動市場成長的主要因素，也是因素之一。

因此，一些國家正在加強早期診斷篩檢，並採取措施支持現有患者。例如，印度政府為在治療期間需要援助的患者發起了「阿尤斯曼·巴拉特」和總理國家救濟基金。同樣，印度政府生物技術部與英國癌症研究部簽署了一項協議，以研究更便宜的診斷和治療方法。

液體活體組織切片解決方案擴大被採用作為 MCED 測試，因為它們易於臨床應用。近年來，綜合性、多癌症診斷藥物方法已獲得監管部門的核准。該領域的突破性進展和正在進行的早期檢測研究正在促進市場成長。此外，循環腫瘤 DNA、細胞外囊泡和循環性腫瘤細胞技術正在為更好的癌症治療鋪平道路。多功能技術可以提供整合解決方案，最大限度地發揮液體活體組織切片的潛力。

使用伴同性診斷的優點是可以減少製藥和診斷公司的整體時間和成本。開發和商業化新分子所需的時間通常為 10 至 15 年。診斷方法和藥物的共同開發可以加快監管核准流程並大幅降低成本。自 2016 年 FDA 發布治療和 IVD伴同性診斷開發指南草案以來，許多製造商鼓勵腫瘤學領域伴同性診斷的開發。預計這將對預測期內的市場成長產生積極影響。

癌症診斷市場報告亮點

  • 按產品分類，消耗品領域在 2023 年佔據最大佔有率，達到 59.98%，預計在預測期內成長最快。
  • 按類型分類，體外診斷 (IVD) 領域佔據主導地位，2023 年佔有率為 52.75%。
  • 由於在人群中傳播意識的舉措不斷增加以及研究和開發活動的增加，預計乳癌應用領域將在預測期內顯著成長。
  • 從最終用途來看，市場以實驗室領域為主，提供高效率的門診病人服務。由於住院人數的增加，預計未來幾年醫院產業將顯著成長。
  • 由於與測試相關的各種好處（包括疾病的早期發現），切片檢查領域預計將以顯著的速度成長。
  • 由於核准的新診斷測試數量不斷增加，北美將在 2023 年主導全球癌症診斷市場。
  • 由於主要企業的普及和存在的增加，預計亞太地區在未來幾年將顯著成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素
    • 癌症發生率上升
    • 技術進步
    • 公共和私人組織加大力度
    • 廣泛的研究和開發，開發新的測試解決方案
  • 市場抑制因素分析
    • 影像診斷成本高
    • 輻射暴露可能會限制電腦斷層掃描的使用
    • 更多採用再生成像診斷系統
  • 營商環境分析
    • SWOT 分析：依因素（政治/法律、經濟/技術）
    • 波特五力分析
    • COVID-19感染疾病的影響分析

第4章 產品經營分析

  • 癌症診斷藥物市場：產品波動分析
  • 裝置
    • 2018-2030年設備市場
    • 病理學設備
    • 影像設備
    • 其他
  • 消耗品
    • 消耗品市場，2018-2030
  • 服務
    • 服務市場，2018-2030

第5章 類型業務分析

  • 癌症診斷藥物市場：類型變異分析
  • IVD
    • IVD市場，2018-2030
    • IVD 市場（按類型），2018-2030 年
    • IVD 市場（按技術），2018-2030 年
  • LDT
    • LDT市場，2018-2030
  • 影像
    • 影像市場，2018-2030
    • 磁振造影(MRI)
    • 電腦斷層掃描 (CT)
    • 正子斷層掃描 (PET)
    • 乳房X光檢查
    • 超音波
    • 其他

第6章 應用業務分析

  • 癌症診斷藥物市場：應用變化分析
  • 乳癌
    • 乳癌市場，2018-2030
  • 大腸直腸癌
    • 大腸直腸癌市場，2018-2030
  • 子宮頸癌
    • 子宮頸癌市場，2018-2030
  • 肺癌
    • 肺癌市場，2018-2030
  • 攝護腺癌
    • 攝護腺癌市場，2018-2030
  • 皮膚癌
    • 皮膚癌市場，2018-2030
  • 血癌
    • 血癌市場，2018-2030
  • 腎癌
    • 腎癌市場，2018-2030
  • 肝癌
    • 2018-2030年肝癌市場
  • 胰臟癌
    • 胰臟癌市場，2018-2030
  • 卵巢癌
    • 卵巢癌市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第7章 最終用途業務分析

  • 癌症診斷藥物市場：最終用途變化分析
  • 醫院
    • 醫院市場，2018-2030
  • 實驗室
    • 實驗室市場，2018-2030
  • 其他
    • 其他癌症診斷藥物市場，2018-2030

第8章 基於檢查的業務分析

  • 癌症診斷藥物市場：測試類型變異分析
  • 切片檢查
    • 切片檢查市場，2018-2030
    • 細針抽吸
    • 核心切片檢查
    • 手術切片檢查
    • 皮膚切片檢查/穿刺切片檢查
    • 其他
  • 其他
    • 其他癌症診斷藥物市場，2018-2030

第9章 產品經營分析

  • 癌症診斷藥物市場：產品波動分析
  • 裝置
    • 2018-2030年設備市場
  • 消耗品套件/試劑
    • 消耗品套件與試劑市場，2018-2030
  • 軟體服務
    • 軟體與服務市場，2018-2030

第10章區域業務分析

  • 癌症診斷市場佔有率：按地區分類，2023 年和 2030 年
  • 北美洲
    • 2018-2030年北美癌症診斷藥物市場
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030年歐洲癌症診斷藥物市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區癌症診斷市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲癌症診斷市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 中東和非洲癌症診斷市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章競爭形勢

  • 參與企業概況
  • 財務績效
  • 參與企業
    • 市場領導
    • 2023 年癌症診斷市場佔有率分析
    • 公司簡介
    • 策略規劃
Product Code: GVR-1-68038-213-6

Cancer Diagnostics Market Growth & Trends:

The global cancer diagnostics market size is expected to reach USD 162.31 billion by 2030, as per the new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.16% from 2024 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister's National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government's Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights:

  • Based on product, the consumables segment held the largest share of 59.98% in 2023 and is anticipated to grow at the fastest growth rate over the forecast period
  • Based on type, in vitro diagnostics (IVD) segment dominated the in 2023 with a share of 52.75% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
  • The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
  • Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
  • The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
  • North America dominated the global cancer diagnostics market in 2023, owing to rise in the number of approvals of new diagnostic tests
  • The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Type Snapshot
  • 2.3. Application and End-use Snapshot
  • 2.4. Test Type Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Prevalence of Cancer
    • 3.4.2. Technological Advancements
    • 3.4.3. Rising Initiatives Undertaken by Public and Private Organizations
    • 3.4.4. Extensive R&D for the Development of Novel Testing Solutions
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Diagnostic Imaging
    • 3.5.2. Radiation Exposure Likely to Limit Usage of CT Scans
    • 3.5.3. Rising Adoption of Refurbished Diagnostic Imaging Systems
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Cancer Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2. Pathology Based-Instruments
      • 4.2.2.1. Slide Staining Systems
      • 4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.2. Tissue Processing Systems
      • 4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.3. Cell Processors
      • 4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
      • 4.2.2.4. PCR Instruments
      • 4.2.2.4.1. PCR Instruments Market, 2018 - 2030 (USD Billion)
      • 4.2.2.5. NGS Instruments
      • 4.2.2.5.1. NGS Instruments Market, 2018 - 2030 (USD Billion)
      • 4.2.2.6. Microarrays
      • 4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
      • 4.2.2.7. Other Pathology-based Instruments
      • 4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.3. Imaging Instruments
    • 4.2.4. Others
  • 4.3. Consumables
    • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
  • 4.4. Services
    • 4.4.1. Services Market, 2018 - 2030 (USD Billion)

Chapter 5. Type Business Analysis

  • 5.1. Cancer Diagnostics Market: Type Movement Analysis
  • 5.2. IVD
    • 5.2.1. IVD Market, 2018 - 2030 (USD Billion)
    • 5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
      • 5.2.2.1. Diagnosis
      • 5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
      • 5.2.2.2. Early Detection
      • 5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
      • 5.2.2.3. Therapy Selection
      • 5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
      • 5.2.2.4. Monitoring
      • 5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
    • 5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
      • 5.2.3.1. Polymerase Chain Reaction (PCR)
      • 5.2.3.1.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.2. In Situ Hybridization (ISH)
      • 5.2.3.2.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.3. Immunohistochemistry (IHC)
      • 5.2.3.3.1. Immunohistochemistry (IHC) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.4. Next-generation Sequencing (NGS)
      • 5.2.3.4.1. Next-generation Sequencing (NGS) Market, 2018 - 2030 (USD Billion)
      • 5.2.3.5. Microarrays
      • 5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
      • 5.2.3.6. Flow Cytometry
      • 5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
      • 5.2.3.7. Immunoassays
      • 5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
      • 5.2.3.8. Other IVD Testing Technologies
      • 5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
  • 5.3. LDT
    • 5.3.1. LDT Market, 2018 - 2030 (USD Billion)
  • 5.4. Imaging
    • 5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
    • 5.4.2. Magnetic Resonance Imaging (MRI)
      • 5.4.2.1. Magnetic Resonance Imaging (MRI) Market, 2018 - 2030 (USD Billion)
    • 5.4.3. Computed Tomography (CT)
      • 5.4.3.1. Computed Tomography (CT) Market, 2018 - 2030 (USD Billion)
    • 5.4.4. Positron Emission Tomography (PET)
      • 5.4.4.1. Positron Emission Tomography (PET) Market, 2018 - 2030 (USD Billion)
    • 5.4.5. Mammography
      • 5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
    • 5.4.6. Ultrasound
      • 5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
    • 5.4.7. Others
      • 5.4.7.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Application Business Analysis

  • 6.1. Cancer Diagnostics Market: Application Movement Analysis
  • 6.2. Breast Cancer
    • 6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
  • 6.3. Colorectal Cancer
    • 6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
  • 6.4. Cervical Cancer
    • 6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
  • 6.5. Lung Cancer
    • 6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
  • 6.6. Prostate Cancer
    • 6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
  • 6.7. Skin Cancer
    • 6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
  • 6.8. Blood Cancer
    • 6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
  • 6.9. Kidney Cancer
    • 6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
  • 6.10. Liver Cancer
    • 6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
  • 6.11. Pancreatic Cancer
    • 6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
  • 6.12. Ovarian Cancer
    • 6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
  • 6.13. Others
    • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. End-Use Business Analysis

  • 7.1. Cancer Diagnostics Market: End-Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 7.3. Laboratories
    • 7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
  • 7.4. Others
    • 7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 8. Test Type Business Analysis

  • 8.1. Cancer Diagnostics Market: Test Type Movement Analysis
  • 8.2. Biopsy
    • 8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.2. Fine-needle Aspiration
      • 8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
    • 8.2.3. Core Biopsy
      • 8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.4. Surgical Biopsy
      • 8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.5. Skin Biopsy /Punch Biopsy
      • 8.2.5.1. Skin Biopsy /Punch Biopsy Market, 2018 - 2030 (USD Billion)
    • 8.2.6. Others
      • 8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
  • 8.3. Others
    • 8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 9. Product Business Analysis

  • 9.1. Cancer Diagnostics Market: Product Movement Analysis
  • 9.2. Instruments
    • 9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 9.3. Consumables Kits and Reagents
    • 9.3.1. Consumables Kits and Reagents Market, 2018 - 2030 (USD Billion)
  • 9.4. Software and Services
    • 9.4.1. Software and Services Market, 2018 - 2030 (USD Billion)

Chapter 10. Regional Business Analysis

  • 10.1. Cancer Diagnostics Market Share By Region, 2023 & 2030
  • 10.2. North America
    • 10.2.1. North America Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.2.2. U.S.
      • 10.2.2.1. Key Country Dynamics
      • 10.2.2.2. Target Disease Prevalence
      • 10.2.2.3. Competitive Scenario
      • 10.2.2.4. Regulatory Framework
      • 10.2.2.5. Reimbursement Scenario
      • 10.2.2.6. U.S. Cancer diagnostics market, 2018 - 2030 (USD BILLION)
    • 10.2.3. Canada
      • 10.2.3.1. Key Country Dynamics
      • 10.2.3.2. Target Disease Prevalence
      • 10.2.3.3. Competitive Scenario
      • 10.2.3.4. Regulatory Framework
      • 10.2.3.5. Reimbursement Scenario
      • 10.2.3.6. Canada Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3. Europe
    • 10.3.1. Europe Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.2. Germany
      • 10.3.2.1. Key Country Dynamics
      • 10.3.2.2. Target Disease Prevalence
      • 10.3.2.3. Competitive Scenario
      • 10.3.2.4. Regulatory Framework
      • 10.3.2.5. Reimbursement Scenario
      • 10.3.2.6. Germany Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.3. UK
      • 10.3.3.1. Key Country Dynamics
      • 10.3.3.2. Target Disease Prevalence
      • 10.3.3.3. Competitive Scenario
      • 10.3.3.4. Regulatory Framework
      • 10.3.3.5. Reimbursement Scenario
      • 10.3.3.6. UK Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.4. France
      • 10.3.4.1. Key Country Dynamics
      • 10.3.4.2. Target Disease Prevalence
      • 10.3.4.3. Competitive Scenario
      • 10.3.4.4. Regulatory Framework
      • 10.3.4.5. Reimbursement Scenario
      • 10.3.4.6. France Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.5. Italy
      • 10.3.5.1. Key Country Dynamics
      • 10.3.5.2. Target Disease Prevalence
      • 10.3.5.3. Competitive Scenario
      • 10.3.5.4. Regulatory Framework
      • 10.3.5.5. Reimbursement Scenario
      • 10.3.5.6. Italy Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.6. Spain
      • 10.3.6.1. Key Country Dynamics
      • 10.3.6.2. Target Disease Prevalence
      • 10.3.6.3. Competitive Scenario
      • 10.3.6.4. Regulatory Framework
      • 10.3.6.5. Reimbursement Scenario
      • 10.3.6.6. Spain Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.7. Denmark
      • 10.3.7.1. Key Country Dynamics
      • 10.3.7.2. Target Disease Prevalence
      • 10.3.7.3. Competitive Scenario
      • 10.3.7.4. Regulatory Framework
      • 10.3.7.5. Reimbursement Scenario
      • 10.3.7.6. Denmark Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.8. Sweden
      • 10.3.8.1. Key Country Dynamics
      • 10.3.8.2. Target Disease Prevalence
      • 10.3.8.3. Competitive Scenario
      • 10.3.8.4. Regulatory Framework
      • 10.3.8.5. Reimbursement Scenario
      • 10.3.8.6. Sweden Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.3.9. Norway
      • 10.3.9.1. Key Country Dynamics
      • 10.3.9.2. Target Disease Prevalence
      • 10.3.9.3. Competitive Scenario
      • 10.3.9.4. Regulatory Framework
      • 10.3.9.5. Reimbursement Scenario
      • 10.3.9.6. Norway Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4. Asia Pacific
    • 10.4.1. Asia Pacific Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.4.2. Japan
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Target Disease Prevalence
      • 10.4.2.3. Competitive Scenario
      • 10.4.2.4. Regulatory Framework
      • 10.4.2.5. Reimbursement Scenario
      • 10.4.2.6. Japan Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.4.3. China
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Target Disease Prevalence
      • 10.4.3.3. Competitive Scenario
      • 10.4.3.4. Regulatory Framework
      • 10.4.3.5. Reimbursement Scenario
      • 10.4.3.6. China Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.4.4. India
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Target Disease Prevalence
      • 10.4.4.3. Competitive Scenario
      • 10.4.4.4. Regulatory Framework
      • 10.4.4.5. Reimbursement Scenario
      • 10.4.4.6. India Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.4.5. South Korea
      • 10.4.5.1. Key Country Dynamics
      • 10.4.5.2. Target Disease Prevalence
      • 10.4.5.3. Competitive Scenario
      • 10.4.5.4. Regulatory Framework
      • 10.4.5.5. Reimbursement Scenario
      • 10.4.5.6. South Korea Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.4.6. Australia
      • 10.4.6.1. Key Country Dynamics
      • 10.4.6.2. Target Disease Prevalence
      • 10.4.6.3. Competitive Scenario
      • 10.4.6.4. Regulatory Framework
      • 10.4.6.5. Reimbursement Scenario
      • 10.4.6.6. Australia Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.4.7. Thailand
      • 10.4.7.1. Key Country Dynamics
      • 10.4.7.2. Target Disease Prevalence
      • 10.4.7.3. Competitive Scenario
      • 10.4.7.4. Regulatory Framework
      • 10.4.7.5. Reimbursement Scenario
      • 10.4.7.6. Thailand Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.5. Latin America
    • 10.5.1. Latin America Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.5.2. Brazil
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Target Disease Prevalence
      • 10.5.2.3. Competitive Scenario
      • 10.5.2.4. Regulatory Framework
      • 10.5.2.5. Reimbursement Scenario
      • 10.5.2.6. Brazil Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.5.3. Mexico
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Target Disease Prevalence
      • 10.5.3.3. Competitive Scenario
      • 10.5.3.4. Regulatory Framework
      • 10.5.3.5. Reimbursement Scenario
      • 10.5.3.6. Mexico Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.5.4. Argentina
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Target Disease Prevalence
      • 10.5.4.3. Competitive Scenario
      • 10.5.4.4. Regulatory Framework
      • 10.5.4.5. Reimbursement Scenario
      • 10.5.4.6. Argentina Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.6. MEA
    • 10.6.1. MEA Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.6.2. South Africa
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Target Disease Prevalence
      • 10.6.2.3. Competitive Scenario
      • 10.6.2.4. Regulatory Framework
      • 10.6.2.5. Reimbursement Scenario
      • 10.6.2.6. South Africa Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.6.3. Saudi Arabia
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Target Disease Prevalence
      • 10.6.3.3. Competitive Scenario
      • 10.6.3.4. Regulatory Framework
      • 10.6.3.5. Reimbursement Scenario
      • 10.6.3.6. Saudi Arabia Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.6.4. UAE
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Target Disease Prevalence
      • 10.6.4.3. Competitive Scenario
      • 10.6.4.4. Regulatory Framework
      • 10.6.4.5. Reimbursement Scenario
      • 10.6.4.6. UAE Cancer diagnostics market, 2018 - 2030 (USD Billion)
    • 10.6.5. Kuwait
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Target Disease Prevalence
      • 10.6.5.3. Competitive Scenario
      • 10.6.5.4. Regulatory Framework
      • 10.6.5.5. Reimbursement Scenario
      • 10.6.5.6. Kuwait Cancer diagnostics market, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

  • 11.1. Participant's overview
  • 11.2. Financial performance
  • 11.3. Participant categorization
    • 11.3.1. Market Leaders
    • 11.3.2. Cancer Diagnostics Market Share Analysis, 2023
    • 11.3.3. Company Profiles
      • 11.3.3.1. ABBOTT
      • 11.3.3.1.1. Company Overview
      • 11.3.3.1.2. Financial Performance
      • 11.3.3.1.3. Product Benchmarking
      • 11.3.3.1.4. Strategic Initiatives
      • 11.3.3.2. GE HEALTHCARE
      • 11.3.3.2.1. Company Overview
      • 11.3.3.2.2. Financial Performance
      • 11.3.3.2.3. Product Benchmarking
      • 11.3.3.2.4. Strategic Initiatives
      • 11.3.3.3. F. HOFFMANN-LA ROCHE LTD.
      • 11.3.3.3.1. Company Overview
      • 11.3.3.3.2. Financial Performance
      • 11.3.3.3.3. Product Benchmarking
      • 11.3.3.3.4. Strategic Initiatives
      • 11.3.3.4. QIAGEN
      • 11.3.3.4.1. Company Overview
      • 11.3.3.4.2. Financial Performance
      • 11.3.3.4.3. Product Benchmarking
      • 11.3.3.4.4. Strategic Initiatives
      • 11.3.3.5. BD
      • 11.3.3.5.1. Company Overview
      • 11.3.3.5.2. Financial Performance
      • 11.3.3.5.3. Product Benchmarking
      • 11.3.3.5.4. Strategic Initiatives
      • 11.3.3.6. SIEMENS HEALTHCARE GMBH
      • 11.3.3.6.1. Company Overview
      • 11.3.3.6.2. Financial Performance
      • 11.3.3.6.3. Product Benchmarking
      • 11.3.3.6.4. Strategic Initiatives
      • 11.3.3.7. THERMO FISHER SCIENTIFIC, INC.
      • 11.3.3.7.1. Company Overview
      • 11.3.3.7.2. Financial Performance
      • 11.3.3.7.3. Product Benchmarking
      • 11.3.3.7.4. Strategic Initiatives
      • 11.3.3.8. HOLOGIC, INC.
      • 11.3.3.8.1. Company Overview
      • 11.3.3.8.2. Financial Performance
      • 11.3.3.8.3. Product Benchmarking
      • 11.3.3.8.4. Strategic Initiatives
      • 11.3.3.9. KONINKLIJKE PHILIPS N.V. (PHILIPS)
      • 11.3.3.9.1. Company Overview
      • 11.3.3.9.2. Financial Performance
      • 11.3.3.9.3. Product Benchmarking
      • 11.3.3.9.4. Strategic Initiatives
      • 11.3.3.10. ILLUMINA, INC.
      • 11.3.3.10.1. Company Overview
      • 11.3.3.10.2. Financial Performance
      • 11.3.3.10.3. Product Benchmarking
      • 11.3.3.10.4. Strategic Initiatives
    • 11.3.4. Strategy Mapping
      • 11.3.4.1. Expansion
      • 11.3.4.2. Acquisition
      • 11.3.4.3. Collaborations
      • 11.3.4.4. Disease Type/Drug Class Launch
      • 11.3.4.5. Partnerships
      • 11.3.4.6. Others

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global cancer diagnostics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 5 Global cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 6 Global cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 7 Global cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 8 North America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 9 North America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 10 North America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 11 North America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 12 North America cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 13 North America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 14 U.S. cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 15 U.S. cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 16 U.S. cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 17 U.S. cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 18 U.S. cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 19 Canada cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 20 Canada cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 21 Canada cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 22 Canada cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 23 Canada cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 24 Europe cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 25 Europe cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 26 Europe cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 27 Europe cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 28 Europe cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 29 Europe cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 30 UK cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 31 UK cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 32 UK cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 33 UK cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 34 UK cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 35 Germany cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Germany cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 37 Germany cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 38 Germany cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 39 Germany cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 40 France cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 41 France cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 42 France cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 43 France cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 44 France cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 45 Italy cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 46 Italy cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 47 Italy cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 48 Italy cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 49 Italy cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 50 Spain cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 51 Spain cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 52 Spain cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 53 Spain cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 54 Spain cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 55 Denmark cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 56 Denmark cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 57 Denmark cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 58 Denmark cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 59 Denmark cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 60 Sweden cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 61 Sweden cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 62 Sweden cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 63 Sweden cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 64 Sweden cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 65 Norway cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 66 Norway cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 67 Norway cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 68 Norway cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 69 Norway cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 70 Asia Pacific cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 71 Asia Pacific cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 72 Asia Pacific cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Asia Pacific cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 74 Asia Pacific cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 76 Japan cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 77 Japan cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 78 Japan cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 79 Japan cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 80 Japan cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 81 China cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 82 China cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 83 China cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 84 China cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 85 China cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 86 India cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 87 India cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 88 India cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 89 India cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 90 India cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 91 South Korea cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 92 South Korea cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 93 South Korea cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 94 South Korea cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 95 South Korea cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 96 Thailand cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 97 Thailand cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 98 Thailand cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 99 Thailand cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 100 Thailand cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 101 Australia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 102 Australia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 103 Australia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 104 Australia cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 105 Australia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 106 Latin America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 107 Latin America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 108 Latin America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 109 Latin America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 110 Latin America cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 111 Latin America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 112 Brazil cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 113 Brazil cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 114 Brazil cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 115 Brazil cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 116 Brazil cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 117 Mexico cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 118 Mexico cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 119 Mexico cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 120 Mexico cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 121 Mexico cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 122 Argentina cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 123 Argentina cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 124 Argentina cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 125 Argentina cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 126 Argentina cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 127 Middle East & Africa cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
  • Table 128 Middle East & Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 129 Middle East & Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 130 Middle East & Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 131 Middle East & Africa cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 132 Middle East & Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 133 South Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 134 South Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 135 South Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 136 South Africa cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 137 South Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 138 Saudi Arabia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 142 Saudi Arabia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 143 UAE cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 144 UAE cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 145 UAE cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 146 UAE cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 147 UAE cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
  • Table 148 Kuwait cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
  • Table 149 Kuwait cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
  • Table 150 Kuwait cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
  • Table 151 Kuwait cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 152 Kuwait cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Cancer diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Product and type segment snapshot
  • Fig. 11 Application segment snapshot
  • Fig. 12 End-use and test type segment snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Cancer diagnostics market value, 2023 (USD Billion)
  • Fig. 15 Market dynamics
  • Fig. 16 Incidence of most common cancers globally, 2020
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 Cancer diagnostics market: Product outlook and key takeaways
  • Fig. 20 Cancer diagnostics market: Product movement analysis
  • Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 22 Pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Slide staining systems market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 24 Tissue processing systems market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 25 Cell processors market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 PCR instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 NGS instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Other pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Imaging instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 32 Consumables market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Kits & reagents market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 35 Probes market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Services market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Cancer diagnostics market: Type outlook and key takeaways
  • Fig. 39 Cancer diagnostics market: Type movement analysis
  • Fig. 40 IVD market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 41 Diagnosis market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Early detection market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Therapy selection market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Monitoring market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 45 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 46 In Situ Hybridization (ISH) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 Immunohistochemistry (IHC) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Next-generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 49 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 50 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 51 Immunoassays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 52 Other IVD testing technologies market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 LDT market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 54 Imaging market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 55 Magnetic Resonance Imaging (MRI) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 56 Computed Tomography (CT) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Positron Emission Tomography (PET) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 58 Mammography market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 59 Ultrasound market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 60 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Cancer diagnostics market: Application outlook and key takeaways
  • Fig. 62 Cancer diagnostics market: Application movement analysis
  • Fig. 63 Breast cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 64 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 66 Lung cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 67 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 68 Skin cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 69 Blood cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 70 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 71 Liver cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 72 Pancreatic cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 73 Ovarian cancer market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 74 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 75 Cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 76 Cancer diagnostics market: End-use movement analysis
  • Fig. 77 Hospitals market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 78 Laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 79 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 80 Cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 81 Cancer diagnostics market: Test type movement analysis
  • Fig. 82 Biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 83 Fine-needle aspiration market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 84 Core biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 85 Surgical biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 86 Skin biopsy/punch biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 88 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 89 Cancer Diagnostics Market revenue, by region, 2023 & 2030 (USD Billion)
  • Fig. 90 Regional marketplace: Key takeaways
  • Fig. 91 Regional marketplace: Key takeaways
  • Fig. 92 North America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 93 Key country dynamics
  • Fig. 94 U.S. cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 95 Cancer incidence, 2018-2030
  • Fig. 96 Ways to obtain coverage
  • Fig. 97 Key country dynamics
  • Fig. 98 Canada cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 99 Cancer incidence, 2018-2030
  • Fig. 100 Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 101 Key country dynamics
  • Fig. 102 UK cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 103 Cancer incidence, 2018-2030
  • Fig. 104 Key country dynamics
  • Fig. 105 Germany cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 106 Cancer incidence, 2018-2030
  • Fig. 107 Key country dynamics
  • Fig. 108 France cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 109 Cancer incidence, 2018-2030
  • Fig. 110 Key country dynamics
  • Fig. 111 Spain cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 112 Cancer incidence, 2018-2030
  • Fig. 113 Key country dynamics
  • Fig. 114 Italy cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 115 Cancer incidence, 2018-2030
  • Fig. 116 Key country dynamics
  • Fig. 117 Denmark cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 118 Target disease prevalence
  • Fig. 119 Key country dynamics
  • Fig. 120 Sweden cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 121 Five most common cancers in Sweden
  • Fig. 122 Key country dynamics
  • Fig. 123 Norway cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 124 Number of new cancer cases in 2020, both sexes, all ages
  • Fig. 125 Rest of Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 126 Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 127 Key country dynamics
  • Fig. 128 Japan cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 129 Cancer incidence, 2018 to 2030
  • Fig. 130 Key country dynamics
  • Fig. 131 China cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 132 Cancer incidence, 2018 to 2030
  • Fig. 133 China regulatory details
  • Fig. 134 Key country dynamics
  • Fig. 135 India cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 136 Cancer incidence, 2018 to 2030
  • Fig. 137 Key country dynamics
  • Fig. 138 Australia cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 139 Cancer incidence, 2018 to 2030
  • Fig. 140 Key country dynamics
  • Fig. 141 Thailand cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 142 Cancer incidence, 2020 to 2030
  • Fig. 143 Key country dynamics
  • Fig. 144 South Korea cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 145 Cancer incidence 2018 to 2030
  • Fig. 146 South Korean regulations in four hierarchical orders
  • Fig. 147 South Korea reimbursement scenario
  • Fig. 148 Rest of Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 149 Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 150 Key country dynamics
  • Fig. 151 Brazil cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 152 Estimated number of new cancer cases in Brazil
  • Fig. 153 Key country dynamics
  • Fig. 154 Mexico cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 155 Estimated number of new cancer cases in Mexico
  • Fig. 156 Key country dynamics
  • Fig. 157 Argentina cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 158 Estimated number of new cancer cases in Argentina
  • Fig. 159 Rest of Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 160 MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 161 Key country dynamics
  • Fig. 162 South Africa cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 163 Cancer prevalence-2018-2030
  • Fig. 164 Key country dynamics
  • Fig. 165 Saudi Arabia cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 166 Cancer prevalence-2018-2030
  • Fig. 167 Key country dynamics
  • Fig. 168 UAE cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 169 Cancer prevalence 2018-2030
  • Fig. 170 Key country dynamics
  • Fig. 171 Kuwait cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 172 Target disease prevalence
  • Fig. 173 Key payers in Kuwait
  • Fig. 174 Rest of MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 175 Key company categorization
  • Fig. 176 Company market share analysis, 2023
  • Fig. 177 Strategic framework